Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 267,760 shares at $21.13 ($5.6M) on 2026-06-23, disclosed to the SEC on 2026-06-26.
Scheduled sale ($5.6M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.13 | 30,774 | $650K | 11.5% |
| 2 | $21.13 | 39,131 | $827K | 14.6% |
| 3 | $21.13 | 77,855 | $1.6M | 29.1% |
| 4 | $21.02 | 19,973 | $420K | 7.4% |
| 5 | $21.02 | 25,397 | $534K | 9.5% |
| 6 | $21.02 | 50,530 |
| $1.1M |
| 18.8% |
| 7 | $21.10 | 5,019 | $106K | 1.9% |
| 8 | $21.10 | 6,382 | $135K | 2.4% |
| 9 | $21.10 | 12,699 | $268K | 4.7% |
| Total | $21.09 avg | 267,760 | $5.6M | 100% |
| Filing → |
| DYN | SELL | 2026-06-30 | $10.7M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |
| DYN | SELL | 2026-04-30 | $4.2M | — | Filing → |